Examples of using Rasitrio in English and their translations into Norwegian
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
If Rasitrio is used during breast- feeding, doses should be kept as low as possible.
Do not take Rasitrio and talk to your doctor if you are taking any of the following medicines.
In patients≥65 years the incidence was 10.2% with Rasitrio versus up to 5.4% with dual combinations.
Rasitrio is contraindicated in patients with hypercalcaemia
Very limited data are available on the use of Rasitrio in patients aged 75 years
Rasitrio is an effective once-a-day antihypertensive treatment in adult patients, regardless of gender,
Other adverse reactions previously reported with one of the individual components may occur with Rasitrio even if not observed in clinical trials.
Rasitrio has been administered to more than 1,155 patients in completed clinical trials,
older treated with Rasitrio.
Rasitrio 300 mg/10 mg/25 mg film-coated tablets are brown,
Each Rasitrio 150 mg/5 mg/12.5 mg film-coated tablet contains 150 mg aliskiren(as hemifumarate), 5 mg amlodipine(as besylate) and 12.5 mg hydrochlorothiazide.
Rasitrio 300 mg/5 mg/12.5 mg film-coated tablets are light pink,
When Rasitrio is used in patients with renal impairment, periodic monitoring of serum electrolytes including potassium,
Rasitrio 150 mg/5 mg/12.5 mg film-coated tablets are violet white,
Rasitrio 300 mg/10 mg/12.5 mg film-coated tablets are light red,
Rasitrio 300 mg/5 mg/25 mg film-coated tablets are pale orange-brown,
than 3 months pregnant. It is also better to avoid Rasitrio in early pregnancy- see Pregnancy section.
Rasitrio was associated with a significant reduction in plasma renin activity(PRA)(-34%)
The incidence of any adverse reactions potentially related to hypotension in a short-term active controlled study was 4.9% with Rasitrio versus up to 3.7% with dual combinations.
Medicinal products affected by serum potassium disturbances: Periodic monitoring of serum potassium is recommended when Rasitrio is administered with medicinal products affected by serum potassium disturbances e.g. digitalis glycosides, antiarrhythmics.